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Objective and design: high plasma levels of Interleukin-6 (IL-6) are found in patients with atherosclerotic disorders.
Recently, a common polymorphism of the IL-6 gene promoter, influencing the transcription rate of the gene, has been
described and associated with atherosclerosis of carotid and coronary arteries. The objective of this study was to test whether
IL-6 gene promoter polymorphism is associated with peripheral artery occlusive disease (PAOD) in a case-control study.
Methods: IL-6 gene promoter polymorphism was evaluated by polymerase chain reaction followed by restriction enzyme
analysis in 84 patients affected by PAOD and 183 controls.
Results: the distribution of IL-6 genotypes was: patients with PAOD: 44 GG, 30 GC, 10 CC; control subjects: 53 GG, 80
GC, 50 CC. The GG genotype was significantly more common in the PAOD group (p5 0.0001), while the CC genotype
was significantly more common in control patients (p 0.005).
Conclusions: this study indicates a strong association between IL-6 gene polymorphism and PAOD and support the
hypothesis that IL-6 and IL-6 gene polymorphism are important in the pathophysiology and evolution of ischaemic diseases
of the lower limbs.
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Several observations hint at the role of inflammatory
mechanisms in the development, maturation and
destabilisation of atherosclerotic plaque.1±4 Inter-
leukin-6 (IL-6) is a multifunctional cytokine produced
by several cell types, including fibroblasts, monocytes,
adipocytes, and endothelial cells, which plays a key
role in driving the acute inflammatory response, and
orchestrates the production of acute phase proteins.5
IL-6 may induce endothelial activation6 or stimulate
fibrinogen synthesis,7 which may itself be directly
pathogenic to the endothelium. Elevated levels of
IL-6 are found in patients with carotid atherosclerosis1
and coronary syndromes8 and have been associated
with increased risk of cerebral ischaemia9 and
future myocardial infarction in an apparently healthy
population.10
Recently, a common genetic polymorphism has been
reported in the ÿ174 promoter region of the IL-6
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C allele), resulting in three possible genotypes, GG,
GC, and CC. This polymorphism is functionally
important, since it influences the transcription rate of
the gene and the plasma concentration of IL-6 protein
appears to be influenced by the G/C genotype.11±13
Interestingly, both carotid atherosclerosis and cor-
onary artery disease (CAD) have been associated
with the ÿ174 G/C polymorphism of the IL-6 gene
promoter.14
The aim of this study was to test the hypothesis
that the IL-6 gene polymorphism is associated with
peripheral artery occlusive disease (PAOD). We ana-
lysed the distribution of IL-6 genotypes and alleles in
a case-control study including 84 PAOD patients and
183 control subjects.
Methods
Subjects
Both patients and controls were recruited among
subjects consecutively admitted to the Department ofl rights reserved.
Table 1. Demographic and clinical data in PAOD patients and
controls.
Patients
(n 84)
Controls
(n 183)
p
Age (years SD) 75 7 76 7 0.41
Male gender 51 (61%) 89 (49%) 0.06
Hypertension 59 (70%) 108 (59%) 0.06
Hypercholesterolaemia 25 (30%) 59 (32%) 0.68
Diabetes 39 (46%) 40 (22%) 0.001
History of CAD 33 (39%) 55 (30%) 0.13
Stroke/TIA 22 (26%) 44 (24%) 0.70
Smoking 55 (65%) 60 (33%) 50.0001
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University Hospital of Rome, from 1 December 2000
to 30 November 2001. Inclusion criteria for the PAOD
group were Caucasian race and presence of PAOD.
Diagnosis of PAOD was performed in accordance
with the criteria established by the Ad Hoc Committee
on Reporting Standards of the Society for Vascular
Surgery and the International Society for Cardiovas-
cular Surgery.15 All patients had an ankle/arm
pressure index lower than 0.8 and were at Fontaine's
stage II, with intermittent claudication and no rest
pain or trophic lesions. Inclusion criteria for the
control group were Caucasian race, absence of
PAOD, and no relationship with cases. All control
subjects presented an ankle/arm pressure index 1
and normal findings on bilateral high-resolution B-
mode ultrasonography evaluation (Echocolor Doppler
Acuson 128XP/10, Acuson, Mountain View, CA,
U.S.A., with an 4 MHz transducer). Exclusion criteria
from the study were tumours, chronic inflammatory
diseases, and autoimmune diseases. At the end of the
recruitment period, a total of 84 PAOD patients and
183 controls were enrolled. All subjects belonged to
independent pedigrees. Informed consent was
obtained from all patients. The study protocol was
accepted by the Ethics Committee of our University
Hospital.
Sample preparation and PCR detection of
IL-6 DNA polymorphism
Nucleic acid isolation from 200 ml of peripheral blood
was carried out by using a DNA extraction kit
(NucleoSpin Blood QuickPure, Macherey-Nagel,
Duren, Germany), as recommended by the supplier.
Genomic DNAs were assayed with polymerase
chain reaction (PCR) for the detection of IL-6 gene,
using the published primer set: 50-TGACTTCAGCTT-
TACTCTTTGT-30 (sense primers) and 50-CTGATTG-
GAAACCTTATTAGG-30 (antisense primers). Briefly,
PCR reaction, containing 0.2 mmol/L of each primer,
0.2 mmol/L of dNTPs (Boehringer GmbH, Mannheim,
Germany), 1.5 mmol/L MgCl2, and 2.5 U of AmpliTaq
polymerase (Perkin-Elmer, Cetus, Norwalk, CT,
U.S.A.) in a final volume of 20 ml, was performed in
a GeneAmp PCR System 9700 (Perkin±Elmer) with an
initial denaturation step of 10 min at 94 C and a
final extension step of 10 min at 72 C. The following
thermal profile was repeated for 35 cycles: denatur-
ation for 1 min at 94 C, annealing for 1 min and 35 s at
55 C and extension for 1 min at 72 C. The amplified
sequence was digested by SfaNI restriction
enzyme (New England BioLabs, Beverly, MA,U.S.A.) at 37 C overnight. The digested products
were electrophoresed in 2% agarose gel and visualised
by ethidium bromide staining. The GG genotype cor-
responded to the contemporary presence of 140 and
58 bp fragments. The GC genotype corresponded to
the contemporary presence of 198, 140, and 58 bp frag-
ments. The CC genotype corresponded to a 198 bp
fragment.
Statistical analysis
Demographic and clinical data between groups were
compared by t-test and Chi-squared test. Genotype
and allele ratio distribution between groups was
analysed by Chi-squared test. A logistic regression
analysis was performed to estimate the association
between genotype and PAOD. Odds ratios were
calculated with 95% confidence interval (CI). Analyses
were done with Intercooled STATA 6.0 for Windows
(Statistics/Data Analysis, Stata Corporation, College
Station, TX, U.S.A.). Statistical significance was
established at p5 0.05.
Results
Demographic and clinical characteristics of patients
and controls are reported in Table 1. Diabetes and
abuse of tobacco were significantly more frequent in
patients than controls (p 0.001 and p5 0.0001,
respectively). Hypertension and gender ratio were
also close to being significantly different. Other risk
factors for PAOD, such as hypercholesterolaemia, his-
tory of coronary artery disease (CAD), stroke or trans-
ient ischaemic attacks (TIA) of the brain, were not
differently distributed between patients and controls.
The distribution of IL-6 genotypes and the allele
ratio in cases and controls is shown in Table 2. Geno-
types were in Hardy-Weinberg equilibrium. The geno-
type distribution was 44 GG, 30 GC, 10 CC in the
84 patients with PAOD and 53 GG, 80 GC, 50 CC inEur J Vasc Endovasc Surg Vol 24, September 2002
Table 2. IL-6 genotype distribution and allele ratio between
groups.
Patients Controls p
All n 84 n 183
GG 44 (52%) 53 (29%) 50.0001
GC 30 (36%) 80 (56%) 0.23
CC 10 (12%) 50 (27%) 0.005
G/C ratio 2.3 1.0 50.0001
Males n 51 n 89
GG 28 (55%) 32 (36%) 0.029
GC 17 (33%) 34 (38%) 0.56
CC 6 (12%) 23 (26%) 0.004
G/C ratio 2.5 1.2 50.0001
Females n 33 n 94
GG 16 (49%) 21 (22%) 0.004
GC 13 (39%) 46 (49%) 0.34
CC 4 (12%) 27 (29%) 0.05
G/C ratio 2.1 0.9 0.003
Table 3. Risk factors for PAOD based on logistic regression
analysis.
Odds ratio 95% CI p
G/G genotype 4.6 1.9±11.04 0.001
G/C genotype 1.7 0.74±4.22 0.197
Diabetes 3.1 1.7±9.34 0.007
Sex M 0.8 0.44±1.59 0.607
Age 0.9 0.95±1.02 0.598
Hypertension 1.7 0.94±3.36 0.074
Hypercholesterolaemia 1.0 0.55±2.03 0.855
History of CAD 1.7 0.94±3.40 0.073
Stroke/TIA 0.6 0.34±1.40 0.311
Smoking 5.7 2.47±13.1 50.0001
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genotype in patients with PAOD (52%) was signifi-
cantly higher than in controls (29%) (p5 0.0001). In
contrast, the frequency of the CC genotype was more
than two times higher in controls than in subjects with
PAOD (27 vs 12%, p 0.005). Likewise, allele ratio was
significantly different between the two groups: the
ratio between the G and C allele frequency was 2.3
in patients with PAOD and 1.0 in controls (p5 0.0001).
In order to evaluate whether the distribution of IL-6
genotypes was influenced by sex, male and female
subjects were separately analysed (Table 2). The
same trend was observed in both men and women:
the incidence of GG genotype was significantly higher
in men, as well as in women affected by PAOD
(p 0.029 and p 0.004, respectively).
The role of the GG genotype in the development of
PAOD was then investigated by logistic regression
analysis (Table 3). We found that the GG genotype is
an independent risk for PAOD in our population and
that subjects carrying the GG genotype have a risk
more than four times higher than CC homozygousEur J Vasc Endovasc Surg Vol 24, September 2002individuals to be affected by the disease [Odds ratio
4.6 (95% CI 1.9±11.04), p 0.001].
Discussion
The initiation and progression of atherosclerosis
involve vessel conformation, haemodynamic forces,
exposure to multiple risk factors, cellular composition,
and inflammation.4,16 The endothelium expresses
procoagulant, instead of anticoagulant, properties
and produces vasoactive molecules, inflammatory
cytokines, and growth factors. This leads to the
accumulation and activation of macrophages and lym-
phocytes within the plaque. Activation of these
inflammatory cells leads to the further release of
hydrolytic enzymes, cytokines, chemokines, and
growth factors,17 inducing damage and eventually
leading to focal necrosis.18
IL-6 is a prototypical inflammatory cytokine able
to damage the endothelium and initiate athero-
sclerosis.19 Immunohistochemical studies of the
human arterial atherosclerotic wall have demon-
strated that IL-6 is expressed in the cellular and extra-
cellular deposits in the connective tissue matrix and
that atherosclerotic plaques have a significantly high
level of IL-6.20 Studies in ApoE-knockout mice, that
spontaneously develop systemic atherosclerosis, also
show elevated levels of IL-6 mRNA in the plaque area
compared with normal mice.21 These data are consist-
ent with the observation of elevated levels of IL-6 in
patients with coronary syndromes and atheroscler-
osis-related diseases.8,22±24 Interestingly, plasma levels
of IL-6 are influenced by the ÿ174 G/C polymorphism
of the IL-6 gene promoter.11 Recent studies have
investigated the possible clinical significance of this
polymorphism and analysed its association with
atherosclerotic and ischaemic diseases, including
carotid atherosclerosis,19 CAD,14 and abdominal aortic
aneurysm.13 However, no studies have been per-
formed in order to test whether the G/C IL-6 gene
polymorphism is associated with atherosclerosis of
the peripheral circulation of lower limbs. Our study
shows for the first time that the distribution of IL-6
genotypes and alleles is different between patients
affected by PAOD and controls. Indeed, the frequency
of the GG genotype and G allele is significantly higher
in PAOD patients. In contrast, control subjects exhibit
a significantly higher frequency of the CC genotype
and C allele. When male and female patients were
separately analysed, a similar distribution of IL-6
genotypes and alleles was found, demonstrating that
the G/C polymorphism of the IL-6 gene is involved in
the pathophysiology of PAOD in both men and
IL-6 Gene Polymorphism and PAOD 267women. We also show, by using logistic regression
analysis, that subjects carrying the G allele have
increased risk of PAOD. In particular, subjects GG
homozygous have a risk 4.6 times higher to develop
the disease, when compared to CC homozygous
patients. Taken together, our data are consistent with
the hypothesis that the ÿ174 G/C polymorphism of
the IL-6 gene promoter is relevant for the pathogenesis
and/or evolution of systemic atherosclerosis.
Several studies have focused on the measurement
and detection of the IL-6 protein in serum or tissue.
However, IL-6 protein levels are influenced by many
pathologic and physiologic conditions, such as infec-
tions, autoimmune disorders, malignancies, trauma,
ischaemia, and drug treatment.25±28 Therefore, a single
measurement might be not predictive of disease in a
given individual. For this reason, our study focuses on
the evaluation of a polymorphism that genetically
determines the plasmatic levels of IL-6.11±13
This study has some potential limitations. In par-
ticular, it is a case-control study and a possible sur-
vival bias cannot be excluded for the patients with
PAOD. In addition, the size of the studied population
is relatively small and our findings need to be con-
firmed in larger samples. Likewise, the association
between IL-6 gene polymorphism and PAOD should
be tested in groups of different ethnic origin. Finally,
we cannot exclude a role played by a gene or by
several genes in linkage disequilibrium with the IL-6
gene, nor that a variant of an other gene, closely linked
to the IL-6 gene, causes the observed association. In
particular, there is strong linkage disequilibrium
between the IL-6 gene promoter polymorphism and
the variable number of tandem repeat polymorphism
of the 30 flanking region of the IL-6 gene.29
In conclusion, this study evaluates for the first time
the association between PAOD and IL-6 gene pro-
moter polymorphism and shows that the GG geno-
type and the G allele are significantly more frequent in
patients affected by PAOD. Although further investi-
gations are needed, our data support the hypothesis
that the IL-6 G/C polymorphism is important in the
pathophysiology of clinically relevant atherosclerotic
disorders.
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